Cervical Cancer Immunotherapy Candidate Launches Phase 3 Study – PrecisionVaccinations
PrecisionVaccinations |
Cervical Cancer Immunotherapy Candidate Launches Phase 3 Study
PrecisionVaccinations There is a group of women battling cervical cancer with a very specific vaccine need. These women have a 50 percent estimated probability of disease recurrence within 4 years of diagnosis. And, the prognosis is very grave for those who experience a … |
